CommercialCoverageLow impact
08.01.99b, Teplizumab-mzwv (Tzield)
Independence Blue Cross·Endocrinology, Pediatrics, Family Medicine +1 more·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
A pharmacy policy for Teplizumab-mzwv (Tzield) has been updated and will be reissued effective May 28, 2025. This appears to be a scheduled policy refresh for a specialized diabetes medication used to delay onset of Type 1 diabetes.
Action Required
By May 28, 2025: Billing team should review the updated Teplizumab-mzwv (Tzield) policy at the provided URL to identify any changes in coverage, prior authorization requirements, or billing procedures for this specialized diabetes medication. Update billing system settings and provider documentation requirements as specified in the full policy.